Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Lexeo Therapeutics

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
From Lexeo Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
From Lexeo Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
From Lexeo Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
From Lexeo Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
From Lexeo Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
From Lexeo Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
From Lexeo Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
From Lexeo Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From LEXEO Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
From LEXEO Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
From LEXEO Therapeutics
Via GlobeNewswire
Tickers LXEO
Lexeo Therapeutics Announces Pricing of Initial Public Offering
From LEXEO Therapeutics
Via GlobeNewswire
LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO’s Cardiovascular Gene Therapies
From LEXEO Therapeutics
Via GlobeNewswire
LEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy
From LEXEO Therapeutics
Via GlobeNewswire
LEXEO Therapeutics Announces Data Presentations at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
From LEXEO Therapeutics
Via GlobeNewswire
LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair
From LEXEO Therapeutics
Via GlobeNewswire
LEXEO Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From LEXEO Therapeutics
Via GlobeNewswire
LEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board
From LEXEO Therapeutics
Via GlobeNewswire
LEXEO Therapeutics to Present Clinical and Preclinical Data at Upcoming Scientific Conferences
From LEXEO Therapeutics
Via GlobeNewswire
LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission
From LEXEO Therapeutics
Via GlobeNewswire
LEXEO Therapeutics to Present New Clinical Data from its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer’s Disease at the 29th European Society of Gene & Cell Therapy Annual Meeting
From LEXEO Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS